GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » Net Debt Paydown Yield %

Clover Biopharmaceuticals (HKSE:02197) Net Debt Paydown Yield % : 84.28% (As of May. 28, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Clover Biopharmaceuticals's Net Debt Paydown Yield % was 84.28%.


Clover Biopharmaceuticals Net Debt Paydown Yield % Historical Data

The historical data trend for Clover Biopharmaceuticals's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Biopharmaceuticals Net Debt Paydown Yield % Chart

Clover Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Debt Paydown Yield %
Get a 7-Day Free Trial - -0.36 -4.83 -23.31 85.94

Clover Biopharmaceuticals Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.83 -26.39 -23.31 31.74 85.94

Competitive Comparison of Clover Biopharmaceuticals's Net Debt Paydown Yield %

For the Biotechnology subindustry, Clover Biopharmaceuticals's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clover Biopharmaceuticals's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Clover Biopharmaceuticals's Net Debt Paydown Yield % falls into.


;
;

Clover Biopharmaceuticals Net Debt Paydown Yield % Calculation

Clover Biopharmaceuticals's Net Debt Paydown Yield % for the quarter that ended in Dec. 2024 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 432.26-172.25 )/302.550436
=85.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Clover Biopharmaceuticals  (HKSE:02197) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Clover Biopharmaceuticals Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of Clover Biopharmaceuticals's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clover Biopharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 758 West Nanjing Road, Room 1901, Jing’an District, Shanghai, CHN
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.
Executives
Liang Peng 2101 Beneficial owner
Liang Joshua G 2501 Other
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Aut-xxi Investment Holdings Limited 2201 Interest of corporation controlled by you
Jnry V Holdings Limited 2101 Beneficial owner
Aut-xxi Hk Holdings Limited 2101 Beneficial owner
Aut-xxi Holdings Limited 2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Super Novel International Limited 2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals Headlines

No Headlines